Article Text

AB0562 A double-blind, placebo-controlled, multicenter trial of tocilizumab in moderate to severe active RA patients with inadequate response to methotrexate in korean population
  1. M.J. Lim1,
  2. S.H. Park2,
  3. S.-C. Shim3,
  4. H.J. Baek4,
  5. D.-H. Yoo5,
  6. H.A. Kim6,
  7. S.K. Lee7,
  8. Y.J. Lee8,
  9. Y.E. Park9,
  10. H.-S. Cha10,
  11. W. Park1,
  12. Y.-W. Song8
  1. 1Rheumatology, Inha University, Incheon
  2. 2Rheumatology, The Catholic University, Seoul
  3. 3Rheumatology, Eulji University, Daejeon
  4. 4Rheumatology, Gachon University, Incheon
  5. 5Rheumatology, Hanyang University
  6. 6Rheumatology, Hallym University
  7. 7Rheumatology, Yonsei University
  8. 8Rheumatology, Seoul National University, Seoul
  9. 9Rheumatology, Pusan National University, Pusan
  10. 10Rheumatology, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic Of


Background Interleukin-6 (IL-6), a proinflammatory cytokine, is thought to play a major pathological role in rheumatoid arthritis (RA). Tocilizumab is humanized anti IL-6 receptor monoclonal antibody which has been shown to improve signs and symptoms of RA.

Objectives To investigate the efficacy and safety of tocilizumab in a Korean population.

Methods This clinical trial was a 24-week phase III, randomized, double-blind, placebo-controlled, multicenter trial with two treatments arms and conducted from October, 2009 to October, 2010. The eligible patients had moderate to severe active RA, inadequately responding to MTX (or DMARDs). Tocilizumab at a dose of 8mg/kg or placebo were administered in a blinded manner, intravenously every 4 weeks, with stable dose of methotrexate (MTX) or other DMARDs.

Results Total of 80 patients completed 24 week’s treatment with 40 patients in each treatment arm. At week 24, proportions of ACR 20, ACR 50, DAS28 remission and EULAR response were significantly higher in Tocilizumab group than in placebo group (p <0.0001, p=0.0002, p=0.0002 and p<0.0001, respectively as shown in Table 1). The mean hemoglobin level was increased and the rheumatoid factor titer was decreased in Tocilizumab group, compared to those of placebo group (p=0.0002, p=0.0055, respectively). Adverse drug reactions were more frequent in Tocilizumab group than in placebo group as follows; increased SGPT (21%), granulocytopenia (17%), leukocytopenia (15%), hypercholesterolemia (13%), pharyngitis (13%), and increased SGOT (10%). There were more incidences of serious adverse drug reactions in Tocilizumab group than in placebo group, but it was not significant (p=0.0548).

Table 1. Parameters of RA activity

Conclusions In Korean population, administration of tocilizumab 8 mg/kg in combination with MTX (with or without other DMARDs) reduced RA activity significantly. Most of RA activity parameters including ACR 20, ACR 50, DAS 28 remission and EULAR response were achieved more frequently in Tocilizumab group than in placebo group. Tocilizumab was generally well tolerated since no safety issue was observed during the study. This study was financially supported by JW Pharmaceutical Co. (KFDA clinical trial-146).

  1. Maini RN, et al. Arthritis Rheum. 2006;54(9):2817-29.

  2. Jones G, et al. Ann Rheum Dis. 2010;69(1):88-96.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.